drugset / Trial / NCT00682448

Metformin for the Prevention of the Metabolic Side-effects of Zyprexa

NCT00682448 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.

Timeline

Start
2007-08
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 2000 mg Oral

Indications